Premium
Cyclin D1 Expression in Melanocytic Lesions of the Skin
Author(s) -
Ramirez J.A.,
Diaz L.K.,
Guitart J.
Publication year - 2005
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.0303-6987.2005.320fw.x
Subject(s) - cyclin d1 , melanoma , immunohistochemistry , staining , pathology , cyclin , nevus , medicine , melanocytic nevus , cell cycle , cancer research , cancer
Background: Progression through the cell cycle is controlled by cyclins, cyclin‐dependent kinases and cyclin‐dependent kinase‐inhibitory proteins. The role of cyclin D1 in the development, progression and prognosis of melanomas is controversial. The goal of this study is to evaluate the role of cyclin D1 in benign and malignant melanocytic lesions of the skin. Methods: A total of 101 melanocytic lesions of the skin including compound nevi (21), intradermal nevi (18), melanoma in situ (3), primary invasive melanoma (30), and metastatic melanoma (29) were evaluated for cyclin D1 overexpression by immunohistochemistry. The following tiered system was used for scoring: 0% of cells with nuclear staining (score 0), 1–19% nuclear staining (score 1), 20–49% nuclear staining (score 2), and 50% or greater nuclear staining (score 3). Results: The average score for primary melanomas was significantly higher compared to nevi (p = 0.0046), and for in situ melanomas compared to primary invasive melanomas (p = 0.011). There was slightly higher level of expression in compound nevi versus intradermal nevi. Conclusion: Our study indicates that cyclin D1 expression is increased in malignant compared to benign melanocytic lesions. Further studies are needed to ascertain the biological role of cyclin D1 in melanocytic lesions of the skin.